B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities.
about
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure.Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.Increases in B-type natriuretic peptide after acute mental stress in heart failure patients are associated with alcohol consumption.Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries.Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study.An extensive DeBakey type IIIb aortic dissection with massive right pleural effusion presenting as abdominal pain and acute anemia: particular case report.B-type natriuretic peptide is an independent predictor of endothelial function in man.Effect of burden and origin sites of premature ventricular contractions on left ventricular function by 7-day Holter monitorTranslating genomic biomarkers into clinically useful diagnostics.Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study.Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults.New Insights Into Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.Magnetic Resonance Imaging-Detected Myocardial Inflammation and Fibrosis in Rheumatoid Arthritis: Associations With Disease Characteristics and N-Terminal Pro-Brain Natriuretic Peptide Levels.Management of asymptomatic severe aortic stenosis.Perioperative serum brain natriuretic peptide and cardiac troponin in elective intracranial surgery.Natriuretic peptides as markers of cardiovascular risk: the story continues.cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications.Clinical implications of defective B-type natriuretic peptide.Predictive factors for high brain (B-type) natriuretic peptide at discharge in properly treated heart failure patients.Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk.Elevated brain natriuretic peptide level in patients undergoing atrial fibrillation ablation: is it a predictor of failed ablation or a mere function of atrial rhythm and rate at a point in time?Decrease in B-Type Natriuretic Peptide Levels and Successful Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure.
P2860
Q30359729-863BC572-0A1F-447A-8A00-CB39AB51BDBBQ33789760-767A933B-5653-41B5-9FF3-641436BA8360Q34093503-4762FC05-535A-4BDF-949B-69D0E4EF8DBFQ35047848-07FAA282-9B4A-4FDA-9009-01936F65F607Q35586340-367E8F86-B2EE-466F-AB6F-0837E6FDCE44Q35697431-E42E4167-5D96-4E3C-B493-BE85DA710767Q35964757-60A5050B-39BA-4B37-B5CF-0E6A657B8DADQ36325549-C86FBF78-FD84-4DEC-B0A1-74FE97FF8AEAQ36411676-5B6D062A-AD21-4A26-9310-DE9A7D2D13F0Q36716456-63705379-3520-47F5-9A80-3ED10CCB40BDQ36749051-2C98D19E-26E8-454E-BB37-7618134556D4Q36790405-D7E1E933-4056-4D2C-AAF2-D41075E5D88AQ37109794-B8403AC1-FD3B-4005-A5B3-8D100E488EA1Q37993133-6DC53AC0-CEA6-465D-A6C6-E416437461A3Q38165710-EB22C8ED-6CC2-457E-BADF-1D80A21A43EFQ38261513-9236EE64-65CA-4103-8A05-1B9D2CDD784BQ39215532-A717DB18-7A81-4129-86A4-F6C7ED18AE6DQ42047460-DA3DA10F-A51C-418A-BE5E-18F8088FADF7Q42503086-C4170574-7D2C-4D76-AB6C-3570A104ADD9Q42997221-66665F3E-4659-4582-AD03-4D8DC43CB5CDQ43066343-753C7E9F-E38F-4BCC-A542-3ABDEFE7F73AQ43219078-7583BDF4-FA1F-4A7C-95B1-21EA9963FD5EQ44635594-2242890A-077F-4C40-9E04-3C26EC39CB7AQ48370529-445EAF1F-B2A3-40AC-B0A1-D3869F1C6B2EQ48790613-2D9E5C6F-1811-4066-90BB-0E24DD1C620DQ52146561-999232D2-F67A-46F5-9CB8-15F7164141AD
P2860
B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
B-type natriuretic peptide as ...... peculations and opportunities.
@ast
B-type natriuretic peptide as ...... peculations and opportunities.
@en
type
label
B-type natriuretic peptide as ...... peculations and opportunities.
@ast
B-type natriuretic peptide as ...... peculations and opportunities.
@en
prefLabel
B-type natriuretic peptide as ...... peculations and opportunities.
@ast
B-type natriuretic peptide as ...... peculations and opportunities.
@en
P356
P1476
B-type natriuretic peptide as ...... peculations and opportunities.
@en
P2093
John C Burnett
P304
P356
10.4065/80.8.1029
P407
P50
P577
2005-08-01T00:00:00Z